The combination of cyclophosphamide, vincristine, and dacarbazine (CVD), introduced by Keiser et al. in 1985 for the treatment of malignant PPC, is the standard regimen, including SDHB patients [121,122,123,124,125]. The gene discussed is SDHB; the disease is primary peritoneal carcinoma.